

OPTIMISING COLLABORATIONS TO FOSTER INNOVATION

R&D UNICANCER, the leading French
academic clinical research organisation
in oncology



ACADEMIC EXCELLENCE IN CANCER RESEARCH, FOR THE BENEFIT OF THE PATIENTS

UNICANCER is one of the largest cancer care and research organisations in Europe.

Established in 1994, R&D UNICANCER is UNICANCER's mutualised clinical and translational research entity. With 150 employees, this integrated structure can rely on 20 French Comprehensive Cancer Centres (FCCCs) grouped together in UNICANCER and located throughout the French territory. R&D UNICANCER works with most public and private hospitals involved in cancer treatment in France, as well as with more than 100 hospitals across Europe and the main international cooperative groups involved in cancer research. R&D UNICANCER is accredited by the Ministry of Health and is eligible for public grants.

Our research priorities

FACILITATE PATIENT ACCESS TO INNOVATION FOR A BETTER CARE

- > Develop innovative research into targeted therapies and immunotherapy programmes
- > Give patients an early access to new therapies thanks to our early phase centres of excellence

PROMOTE CLINICAL RESEARCH IN AREAS NEGLECTED BY THE PHARMACEUTICAL INDUSTRY

- > Rare cancers, paediatric & elderly populations, surgery, radiotherapy, supportive care

ENCOURAGE TRANSLATIONAL RESEARCH AND INCREASE CANCER KNOWLEDGE IN ORDER TO DEVELOP FUTURE THERAPEUTIC WEAPONS

- > Biological samples are collected in every clinical trial, with open access for research


OPTIMISE THERAPEUTIC STRATEGIES

- > Design studies to adapt treatments and therapeutic sequences according to prognostic criteria

BETTER UNDERSTAND THE DIFFERENT STANDARDS OF TREATMENT, THE MECHANISMS OF TREATMENT RESPONSE, TOXICITIES AND RESISTANCE

- > Generate large prospective or retrospective epidemiological cohorts

What R&D UNICANCER can bring to your organisation



UNICANCER EXPERT GROUPS

To fulfil its objectives, R&D UNICANCER works closely with internationally recognised groups of experts and provides the necessary support structure for efficient project management.

UNICANCER tumour groups

All UNICANCER tumour groups share common goals:

- > to evaluate existing and new therapeutic strategies
- > to improve patient prognosis and quality of life through personalised treatments
- > to develop innovative approaches to cancer treatment
- > to identify predictors of treatment response, resistance and toxicity.



French Breast Cancer Intergroup (UCBG)*

President: Dr Suzette DELALOGUE, Gustave Roussy, Villejuif

Collaborations

French / EU level: INCa / GENMED / European academic groups (UK NCRN, SAKK, GBG) / European intergroups (BIG, EORTC)

International level: SWOG, MCCRC

Strategic priorities: Subtypes with poor prognosis / biology-driven strategies of therapeutic de-escalation / long-term follow-up data



Genitourinary Group (GETUG)*

President: Prof. Stéphane CULINE, Saint-Louis Hospital, Paris

Collaborations

French / EU level: AFU / CeRePP / GERICO / AFSOS / EORTC / PEACE (Prostate Consortium in Europe) / EBMT

International level: Various key hospitals leaders in the genitourinary field

Strategic priorities: biobanking / proof of concept studies / therapeutic strategies evaluation / real-life data / medical economics



Gastrointestinal Group (UCGI)

President: Dr David MALKA, Gustave Roussy, Paris

Collaborations


French / EU level: FFCD & GERCOR within the PRODIGE intergroup / EORTC

International level: NCI of Canada / Canadian Cancer Trials Group

Strategic priorities: translational research / innovative studies / improvement of therapeutic strategies in adjuvant and metastatic setting

To achieve these goals, the UNICANCER tumour groups develop **strategic clinical research programs with a strong translational component** that relies upon a systematic centralised banking of biological samples.

These clinical studies involve the FCCCs' units and platforms as well as a large number of public and private hospitals in France. All UNICANCER tumour groups are moving towards **international clinical trials** thanks to **various partnerships** with other cooperative groups and strong collaborations with industry.



Sarcoma Group*

President: Prof. Jean-Yves BLAY, Léon Bérard Centre, Lyon

Collaborations

French / EU level: INCa / GSF-GETO French Sarcoma Group / Go-AJA / INTERSARC / EORTC / EuroEwing consortium / Patient Advocacy Groups

Strategic priorities: improvement of initial management of sarcomas and rare connective tissue tumours / biobanking / translational research



Head & Neck Group (UCH&N)

President: Prof. Joël GUIGAY, Antoine Lacassagne Centre, Nice

Collaborations

French / EU level: GORTEC, GETTEC, GERCOR within the head & neck intergroup / EORTC

Strategic priorities: early-phase studies / rare cancers / biology-driven medicine

LEXICON

AFSOS: French Association of Supportive care in cancer

AFU: French Association of Urology

BIG: Breast International Group

CeRePP: Research group on prostate cancer and urologic tumours

EBMT: European Society for Blood and Marrow Transplantation

EORTC: European Organisation for Research and Treatment of Cancer

FFCD: French group of Digestive Oncology

GBG: German Breast Group

GENMED: Laboratory of Excellence in MEDical GENomics

GERCOR: Multidisciplinary Cooperative Group in Oncology

GETTEC: French Head & Neck cancer Study Group

GORTEC: Cooperative Group of Radiation therapy for head and neck cancer

Go-AJA: Adolescents and Young Adults onco-haematology Group

INCa: French National Cancer Institute

INTERMARC: French network of Cooperative Groups in the field of sarcoma

MCCRC: Mayo Clinic Cancer Research Consortium

SAKK: Swiss Group for Clinical Cancer Research

SWOG: SouthWest Oncology Group

UK NCRN: UK National Cancer Research Network

* INCa accredited-group

UNICANCER expert groups are multidisciplinary groups focused on developing and steering innovative clinical studies. Their goals are to optimise treatment strategies and to contribute to scientific education and dissemination in their field,

through participation in conferences and publications. The French National Cancer Institute (INCa) has granted its quality label to four R&D UNICANCER expert groups, thus acknowledging their operating capability and excellence.

UNICANCER cross-pathology groups



Oncogeriatrics Group (GERICO)*

The **UNICANCER Oncogeriatrics Group** forms, together with the UCOG oncogeriatric coordination units, the DIALOG intergroup, which is accredited by INCa. It brings together oncologists, geriatricians, radiotherapists, surgeons, biostatisticians and pharmacologists, all working towards promoting clinical research and innovation in oncogeriatrics and tailoring clinical trials for the elderly population by adapting methodological approaches and rationalising diagnostics and treatments.

President: Dr Étienne BRAIN, Curie Institute – René Huguenin Hospital, Saint-Cloud



Personalised Medicine Programme

The **UNICANCER Personalised Medicine Programme** develops multidrug predictors to enable the selection of the most effective treatments for individual patients. This multidisciplinary group of experts in biology-driven medicine develops programmes aimed at: proof of concept for personalised treatments, identification of predictors of sensitivity or resistance to therapy, identification of biomarkers of relapse or extreme responses and validation of therapeutic decision algorithms based on biological tests. Cross-pathology trials are developed in close collaboration with several tumour-specific groups in France.

President: Prof. Fabrice ANDRÉ, Gustave Roussy, Villejuif



Early Phase Group (GEP)

The **UNICANCER Early Phase Group** has become an important player in France, acknowledged by academic and industrial partners for the quality of its phase I and phase II trials. It is committed to providing patients with early access to innovative treatments by designing increasingly complex trials according to the latest methodologies and research developed in the area of precision medicine.

President: Dr Thomas BACHELOT, Léon Bérard Centre, Lyon



Supportive Care Intergroup

The **UNICANCER-AFSOS Supportive Care Intergroup** has set itself the ambitious goal to design and conduct high-standards clinical programmes using the most up-to-date and optimal methodology available, including the evaluation of quality of life and, whenever possible, a cost-efficiency analysis. Building a bridge with humanities and social sciences has also become key to this group.

President: Prof. Ivan KRAKOWSKI, Bergonié Institute, Bordeaux



Translational Research and Development in Radiation Oncology (UNITRAD)

The **UNICANCER Translational Research and Development in Radiation Oncology Group's** goal is to promote innovative and strategic radiotherapy research programmes, and to develop collaborative networks. Its experts work on numerous of topics such as brachytherapy, imaging, modelling and radiomics, radiobiology and radiopotentialisation, ionising radiation, quality assurance and methodology.

President: Prof. David AZRIA, Montpellier Cancer Institute, Montpellier



Immuno-Oncology Group

Established in 2016, the **UNICANCER Immuno-Oncology Group** embodies UNICANCER's strong desire to be a major player in cancer immunotherapy research. Bringing together renowned researchers and clinicians from the areas of immunology and oncology, this group offers a framework for cross-fertilisation and a dozen clinical and translational studies involving immune checkpoint inhibitors are already underway.

President: Prof. Frédérique Penault-Llorca, Jean Perrin Centre, Clermont-Ferrand

SHAPING FUTURE RESEARCH: R&D UNICANCER FLAGSHIP PROGRAMS

CANTO

This large prospective cohort study aims to quantify and predict treatment-related chronic toxicities, and to evaluate psychological, social and economic impact of these toxicities in patients with non-metastatic breast cancer. Over 10,000 women have been included since 2012.

SAFIR

These “umbrella” studies assess the efficacy of high-throughput genome analysis as a therapeutic decision tool for patients with metastatic breast cancer or metastatic non-small cell lung cancer.

AcSé

These “basket” studies, led by UNICANCER under the auspices of the French NCI (INCa), provide secure access to innovative, targeted therapies (crizotinib and vemurafenib, so far) for patients (including children) with tumours harbouring the corresponding molecular signature. A new AcSé programme has just started, enabling the treatment of patients with rare cancers with anti-PD-1 immunotherapies, namely nivolumab and pembrolizumab.

ESME

Launched in 2014, ESME is the first French independent academic “real life” database in oncology, centralising all longitudinal data available in routine practice. Its aim is to describe the use of cancer treatments and assess available therapeutic strategies. Two initial programmes are ongoing in breast and ovarian cancers.

EXPRESS

This cohort study, started in 2016, aims to identify genetic characteristics unique to patients presenting an unexpected and exceptional response to targeted therapies approved in France. The response of 264 patients with diverse solid tumours will be analysed in separate multidrug cohorts according to tumour type.

..... FRENCH COMPREHENSIVE CANCER CENTRES (FCCCS)*

**19,000
employees**

and more than 135,000 patients hospitalised each year – mainly with solid tumours

Approximately

500

active clinical trials

17%

of the patients treated in the **FCCCs** are included in a clinical trial, **vs 8.5% of cancer patients** in France as a whole

..... PLATFORMS AND RESEARCH UNITS OF EXCELLENCE*

19

FCCCs are INCa-certified **Molecular biology platforms**

7

FCCCs are INCa-certified **integrated cancerology research sites (SIRIC)** out of 8 in France

12

FCCCs are INCa-certified **early-phase clinical trial Centres (CLIP²)**, out of 16 in France

..... R&D UNICANCER SPONSORED RESEARCH*

76

ongoing clinical trials

250

investigator sites involved in 2015, including 100 located in 12 other European countries

5400

patients included in 2016 (5,000 in 2014 and 2015)

* 2016 figures

We are your academic partner of choice in oncology research

R&D unicancer is a mutualised research organisation, unique in france, dedicated to increasing knowledge about cancer and its response to treatment, to optimising therapeutic strategies and to accelerating patient access to innovative treatments.

To serve this goal, **our ambition is to develop customised and mutually beneficial partnerships with public and private stakeholders** involved in oncology research both in France and internationally, and to create **new networks structured around innovation**.

We believe that our technical extensive network of experts and scientific collaborations, our research portfolio, our technical platform, as well as our integrated structure and our independence conferred by the private though non-commercial status, **put R&D UNICANCER in the best position to address your research challenges**.



R&D UNICANCER
101 rue de Tolbiac
75013 Paris
France

Christian CAILLIOT
Director of R&D UNICANCER
c-cailliot@unicancer.fr

Anne-Laure MARTIN
Development, Partnerships
and Strategic Alliances Director
al-martin@unicancer.fr

Camille BARON
Partnerships
and Dissemination officer
c-baron@unicancer.fr

About UNICANCER

UNICANCER groups together the 20 French Comprehensive Cancer Centres (FCCCs) which are private, not-for-profit hospitals located across French territory.

FCCCs are dedicated to fighting cancer through a threefold mission of patient care, research and education. They contribute to the public hospital service in accordance with statutory fees, with no additional charge.

For more information, please visit our website: <http://www.unicancer.fr/en>

About our charity partners

We are in close long-term partnerships based on shared research areas with the French League Against Cancer and the ARC Foundation, two not-for-profit organisations that subsidise cancer research.

